Cost effectiveness analysis of etanercept versus infliximab in the treatment of rheumatoid arthritis patients

被引：0
|
作者：
Malone, DC
Ortmeier, BG
机构：
[1] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
[2] Amgen Corp, Reg Med Liaison, Thousand Oaks, CA 91320 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2003年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：353 / 353
页数：1
相关论文
共 50 条
  • [11] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN MEXICO
    Vargas-Valencia, J.
    Sotelo-Guzman, M.
    Mould-Quevedo, J. F.
    Mucino-Ortega, E.
    Galindo-Suarez, R. M.
    VALUE IN HEALTH, 2011, 14 (03) : A127 - A127
  • [12] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN PORTUGAL
    Mateus, C.
    Moura, A.
    VALUE IN HEALTH, 2014, 17 (07) : A380 - A381
  • [13] Etanercept versus infliximab plus methotrexate in rheumatoid arthritis: A cost-effectiveness analysis from the Italian NHS perspective
    Lopatriello, S
    Berto, P
    VALUE IN HEALTH, 2003, 6 (06) : 725 - 725
  • [14] Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis
    Hoshino, Motoaki
    Yoshio, Taku
    Onishi, Sachiko
    Minota, Seiji
    MODERN RHEUMATOLOGY, 2012, 22 (04) : 532 - 540
  • [15] A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
    Chen, Y-F
    Jobanputra, P.
    Barton, P.
    Jowett, S.
    Bryan, S.
    Clark, W.
    Fry-Smith, A.
    Burls, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2006, 10 (42) : 1 - +
  • [16] A difference in effectiveness between infliximab, etanercept and adalimumab in patients with rheumatoid arthritis.
    Kievit, Wietske
    Fransen, Jaap
    Kuper, Ina H.
    van de Laar, Mart A. F. J.
    Jansen, Tim L.
    De Rooij, Dirk jan R. A. M.
    de Gendt, Carla M.
    Ronday, Karel H.
    Brus, Herman L. M.
    van Ooijen, Piet C. M.
    van Riel, Piet C. L. M.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S309 - S310
  • [17] A Cost-Cost Study Comparing Etanercept with Infliximab in Rheumatoid Arthritis
    Mark J. C. Nuijten
    Peter Engelfriet
    Klaas Duijn
    George Bruijn
    David Wierz
    Marc Koopmanschap
    PharmacoEconomics, 2001, 19 : 1051 - 1064
  • [18] A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis
    Nuijten, MJC
    Engelfriet, P
    Duijn, K
    Bruijn, G
    Wierz, D
    Koopmanschap, M
    PHARMACOECONOMICS, 2001, 19 (10) : 1051 - 1064
  • [19] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN INSTITUTIONAL MARKET IN ECUADOR
    Albuja, M. F.
    Torres, F. G.
    Mould, J.
    Estevez, C.
    VALUE IN HEALTH, 2013, 16 (07) : A717 - A717
  • [20] LONG-TERM COST-EFFECTIVENESS ANALYSIS OF THE TREATMENT WITH INFLIXIMAB, ETANERCEPT AND ADALIMUMAB IN RHEUMATOID ARTHRITIS PATIENTS IN REAL-LIFE CLINICAL PRACTICE
    Cardenas, M.
    de la Fuente, S.
    Font-Ugalde, P.
    Castro-Villegas, M. C.
    Romero-Gomez, M.
    Ruiz-Vilchez, D.
    Calvo-Gutierrez, J.
    Ortega-Castro, R.
    Escudero-Contreras, A.
    Casado, M. A.
    Collantes, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 703 - 703
12345